Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23300674 | 0.92 | ENPP1 (0.41) | NCF1FGFR4 | |
| SCHEMBL16668835 | 0.86 | FGFR4 (0.36) | NCF1FGFR4 | |
| SCHEMBL16668108 | 0.82 | FGFR4 (0.38) | FGFR4 | |
| SCHEMBL29979865 | 0.82 | PRKCQ (0.38) | FGFR4 | |
| SCHEMBL19630148 | 0.82 | PRKCQ (0.38) | FGFR4 | |
| SCHEMBL25491262 | 0.82 | FGFR4 (0.52) | FGFR4 | |
| SCHEMBL16667970 | 0.81 | FGFR4 (0.37) | FGFR4 | |
| SCHEMBL29979050 | 0.80 | PRKCQ (0.41) | FGFR4 | |
| SCHEMBL19629910 | 0.80 | PRKCQ (0.41) | FGFR4 | |
| SCHEMBL19630108 | 0.80 | FGFR4 (0.38) | FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4053126-B1 | BRIDGED CYCLOFORMYLPYRIDINE DERIVATIVE AND USE THEREOF | BROADENBIO CO LTD (CN) | 2025-11-19 | — | — | EP | disclosed |
| US-12344611-B2 | Bridged cycloformylpyridine derivatives and uses thereof | BROADENBIO CO., LTD. (CN) | 2025-07-01 | — | — | US | disclosed |
| CN-116102549-B | 5-Aldehyde heterocyclic amide compound and application thereof | 暨南大学 | 2025-02-11 | — | — | CN | disclosed |
| CN-114650991-B | Bridged ring aldehyde pyridine derivative and application thereof | 北京伯汇生物技术有限公司 | 2024-10-18 | — | — | CN | disclosed |
| US-11667631-B2 | FGFR4 inhibitor, preparation method therefor, and applications thereof | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-06-06 | — | — | US | disclosed |
| US-11667631-B2 | FGFR4 inhibitor, preparation method therefor, and applications thereof | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-06-06 | — | — | US | disclosed |
| WO-2023082044-A1 | 5-FORMYL HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | 暨南大学 | 2023-05-19 | — | — | WO | disclosed |
| WO-2023082044-A1 | 5-FORMYL HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | 暨南大学 | 2023-05-19 | — | — | WO | disclosed |
| CN-116102549-A | 5-aldehyde heterocyclic amide compound and application thereof | 暨南大学 | 2023-05-12 | — | — | CN | disclosed |
| US-11608332-B2 | FGFR4 inhibitor and preparation method and use thereof | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-03-21 | — | — | US | disclosed |
| US-20160304489-A1 | Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide | NOVARTIS AG (CH) | 2016-10-20 | — | — | US | disclosed |
| WO-2016151500-A1 | PARTICLES OF N-(5-CYANO-4-((2-METHOXYETHYL)AMINO)PYRIDIN-2-YL)-7-FORMYL-6-((4-METHYL-2- OXOPIPERAZIN-1-YL)METHYL)-3,4-DIHYDRO-1,8-NAPHTHYRIDINE-1(2H)-CARBOXAMIDE | NOVARTIS AG (CH) | 2016-09-29 | — | — | WO | disclosed |
| WO-2016151499-A1 | FORMYLATED N-HETEROCYCLIC DERIVATIVES AS FGFR4 INHIBITORS | NOVARTIS AG (CH) | 2016-09-29 | — | — | WO | disclosed |
| WO-2016151501-A1 | PHARMACEUTICAL COMBINATIONS | NOVARTIS AG (CH) | 2016-09-29 | — | — | WO | disclosed |
| EP-3060563-A1 | RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS | Novartis AG (CH) | 2016-08-31 | — | — | EP | disclosed |
| US-20160102092-A1 | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | NOVARTIS AG (CH) | 2016-04-14 | — | — | US | disclosed |
| WO-2016054483-A1 | USE OF RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS | NOVARTIS AG (CH) | 2016-04-07 | — | — | WO | disclosed |
| US-9266883-B2 | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | NOVARTIS AG (CH) | 2016-02-23 | — | — | US | disclosed |
| US-20150119385-A1 | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | NOVARTIS AG (CH) | 2015-04-30 | — | — | US | disclosed |
| WO-2015059668-A1 | RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS | NOVARTIS AG (CH) | 2015-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119385-A1 | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | FGFR4, FGFR1, FGFR3 | NCF1 4166/4885FGFR4 1/4885 |
| US-20160304489-A1 | Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NT5C, NUP205 | NCF1 1515/4885FGFR4 1690/4885 |
| US-20160102092-A1 | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | FGFR4, FGFR1, FGFR3 | NCF1 4166/4885FGFR4 1/4885 |
| US-11667631-B2 | FGFR4 inhibitor, preparation method therefor, and applications thereof | FGFR4, FGFR1, FGFR2 | NCF1 1196/4885FGFR4 1/4885 |
| US-11608332-B2 | FGFR4 inhibitor and preparation method and use thereof | FGFR4, FGFR1, FGFR2 | NCF1 1419/4885FGFR4 1/4885 |
| US-12344611-B2 | Bridged cycloformylpyridine derivatives and uses thereof | FGFR4, FGFR1, FGFR3 | NCF1 3485/4885FGFR4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.